NIOX GroupCSSPF 77 PS Ratio is 5.19 as of Jun. 25, 2026, which is 17% below its 10-year median of 6.22. GuruFocus rates CSSPF with a GF Score™ of 77/100 and a GF Value™ of $1.21 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 804 Medical Devices & Instruments companies, NIOX Group ranks worse than 70.27% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, NIOX Group's share price is $0.79965.
NIOX Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.15. Hence, NIOX Group's PS Ratio for today is 5.19.
Good Sign:
NIOX Group PLC stock PS Ratio (=5.05) is close to 3-year low of 4.84.
The historical rank and industry rank for NIOX Group's PS Ratio or its related term are showing as below:
CSSPF'
s PS Ratio Range Over the Past 10 Years
Min: 1.09 Med: 6.22 Max: 23.77
Current: 5.05
During the past 13 years, NIOX Group's highest PS Ratio was 23.77. The lowest was 1.09. And the median was 6.22.
CSSPF's PS Ratio is ranked worse than 70.27% of 804
companies
in the Medical Devices & Instruments industry
Industry Median: 2.855
vs CSSPF: 5.05
During the past 12 months, the average Revenue per Share Growth Rate of NIOX Group was 22.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 17.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 12.90% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 1.80% per year.
During the past 13 years, NIOX Group's highest 3-Year average Revenue per Share Growth Rate was 48.20% per year. The lowest was -24.30% per year. And the median was 6.95% per year.
Back to Basics: PS Ratio
NIOX Group (OTCPK:CSSPF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
NIOX Group PS Ratio Related Terms
NIOX Group PS Ratio Historical Data
* Premium members only.
The historical data trend for NIOX Group's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, NIOX Group's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NIOX Group PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NIOX Group's PS Ratio distribution charts can be found below:
* The bar in red indicates where NIOX Group's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
NIOX Group's Share Price of today is $0.79965.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. NIOX Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.15.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
NIOX Group (CSSPF) has a PS Ratio of 5.19 as of Jun. 25, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on NIOX Group and its competitors. This is 17% below median its historical median of 6.22. Over the past decade, NIOX Group's PS Ratio has ranged from 1.09 to 23.77. According to the industry distribution chart, NIOX Group ranks #565 out of 804 companies in the Medical Devices & Instruments industry, placing it in the top 70.3%.
Is NIOX Group's PS Ratio too high?
NIOX Group's current PS Ratio of 5.19 is 17% below median its 10-year median of 6.22. Over the past 10 years, this metric has ranged from a low of 1.09 to a high of 23.77. The Medical Devices & Instruments industry median PS Ratio is 2.86. NIOX Group's value of 5.19 is 81.8% above this industry median. Based on the distribution chart, NIOX Group ranks #565 out of 804 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, NIOX Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NIOX Group's PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, NIOX Group ranks #565 out of 804 companies for PS Ratio. This places NIOX Group in the lower half of its industry. The industry median PS Ratio is 2.86. NIOX Group's value of 5.19 is 81.8% above this benchmark. Historically, NIOX Group's own PS Ratio has ranged from 1.09 to 23.77 over the past decade. While the company's 10-year median is 6.22 vs. the industry median of 2.86, NIOX Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.86, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NIOX Group's current PS Ratio of 5.19 is 81.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on NIOX Group and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NIOX Group's current PS Ratio is 5.19, which is 17% below median its own 10-year median of 6.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NIOX Group stock overvalued right now?
Based on GuruFocus' analysis, NIOX Group (CSSPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $1.21, compared to a current price of $0.80 — trading 33.9% below its estimated fair value. The current PS Ratio is 5.19, which is 17% below median its 10-year median of 6.22 and 81.8% above the Medical Devices & Instruments industry median of 2.86. NIOX Group's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For NIOX Group (CSSPF), the current PS Ratio is 5.19 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NIOX Group (CSSPF) Overvalued in 2026?
Based on GuruFocus' analysis, NIOX Group stock appears to be undervalued.
The current stock price of $0.80 is trading 33.9% below its estimated GF Value™ of $1.21.
GuruFocus considers NIOX Group to be Significantly Undervalued.
Key valuation signals for CSSPF:
PS Ratio: 5.19 (17% below median its 10-year median of 6.22)
GF Value™: $1.21 vs. price of $0.80 (33.9% below fair value)
Industry Position: 81.8% above the Medical Devices & Instruments median (#565 of 804)
No single metric tells the full story. See the CSSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NIOX Group PLC is engaged in improving the diagnosis, monitoring and management of both asthma and COPD by providing greater patient access to FeNO testing. The company is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for type 2 inflammation which is present in asthma and COPD. Its device, NIOX VERO, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis, monitoring and management of asthma and COPD. It operates in single segment of NIOX relates to the portfolio of products used to improve asthma diagnosis, monitoring and management by measuring fractional exhaled nitric oxide (FeNO).
77GF Score
Get the complete analysis for CSSPF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSSPF has been successfully added to your 
